Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 4, 2004 - Issue 5
Submit an article Journal homepage
25
Views
3
CrossRef citations to date
0
Altmetric
Review

Vaccination with T cell-defined antigens

Monica C Panelli National Institutes of Health, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg 10, R-1C711, Bethesda, MD 20892, USA. [email protected]
,
Ena Wang National Institutes of Health, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg 10, R-1C711, Bethesda, MD 20892, USA. [email protected]
,
Vladia Monsurrò National Institutes of Health, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg 10, R-1C711, Bethesda, MD 20892, USA. [email protected]
,
Ping Jin National Institutes of Health, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg 10, R-1C711, Bethesda, MD 20892, USA. [email protected]
,
Katia Zavaglia National Institutes of Health, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg 10, R-1C711, Bethesda, MD 20892, USA. [email protected]
,
Kina Smith National Institutes of Health, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg 10, R-1C711, Bethesda, MD 20892, USA. [email protected]
,
Yvonne Ngalame National Institutes of Health, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg 10, R-1C711, Bethesda, MD 20892, USA. [email protected]
&
Francesco M Marincola National Institutes of Health, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg 10, R-1C711, Bethesda, MD 20892, USA. [email protected]
 show all
Pages 697-707 | Published online: 03 Mar 2005

Bibliography

  • PARMIANI G, CASTELLI C, DALERBA P et al.: Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?J. Natl. Cancer Inst. (2002) 94:805–818.
  • MARINCOLA FM, WANG E, HERLYN M, SELIGER B, FERRONE S: Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol. (2003) 24:334–341.
  • PARMIANI G, CASTELLI C, RIVOLTINI Let al.: Immunotherapy of melanoma. Semin. Cancer Biol. (2003) 13:391–400.
  • TALEBI T, WEBER JS: Peptide vaccine trials for melanoma: preclinical background and clinical results. Semin. Cancer Biol. (2003) 13:431–438.
  • MARINCOLA FM, FERRONE S: Immunotherapy of melanoma: the good news, the bad news and what to do next.Semin. Cancer Biol. (2003) 13:387–389.
  • SPEISER DE, PITTET MJ, RIMOLDI D et al.: Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor specific T cells. Semin. Cancer Biol. (2003) 13:461–472.
  • HSUEH EC, MORTON DL: Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin. Cancer Biol. (2003) 13:401–407.
  • SONDAK VK, SOSMAN J: Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: melacine. Semin. Cancer Biol. (2003) 13:409–415.
  • ANDERSEN MH, GEHL J, REKER S et al.: Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin. Cancer Biol. (2003) 13:449–459.
  • HORIG H, KAUFMAN HL: Local delivery of poxvirus vaccines for melanoma. Semin. Cancer Biol. (2003) 13:417–422.
  • KOMENAKA I, HOERIG H, KAUFMAN HL: Strategies for the biological therapy of melanoma. Semin. Cancer Biol. (2004) (In Press).
  • MONSURRO V, WANG E, PANELLI MC et al.: Active-specific immunization against cancer: is the problem at the receiving end? Semin. Cancer Biol. (2003) 13:473–480.
  • PACZESNY S, UENO H, FAY J, BANCHEREAU J, PALUCKA K: Dendritic cells as vectors for immunotherapy of cancer. Semin. Cancer Biol. (2003) 13:439–447.
  • SCHEIBENBOGEN C, LETSCH A, SCHMITTEL A, ASEMISSEN AM, THIEL E, KEILHOLZ U: Rational peptide-based tumor vaccine development and T cell monitoring. Semin. Cancer Biol. (2003) 13:423–429.
  • COLACO CA: Cancer immunotherapy: simply cell biology? Trends MoL Med. (2004) 9(12):515–516.
  • FUCHS EJ, MATZINGER P: Is cancer dangerous to the immune system? Semin. ImmunoL (1996) 8:271–280.
  • MATZINGER P: Danger model of immunity. Scand. J. ImmunoL (2001) 54:2–3.
  • OCHSENBEIN AF, KLENERMAN P, KARRER U et al.: Immune suerveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA (1999) 96:2233–2238.
  • MONSURRO V, WANG E, YAMANO Y et al.: Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood (2004) (In Press).
  • MARINCOLA FM, JAFFE EM, HICKLIN DJ, FERRONE S: Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. ImmunoL (2000) 74:181–273.
  • DUNN GP, BRUCE AT, IKEDA H, OLD LJ, SCHREIBER RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat. ImmunoL (2002) 3:991–998.
  • KHONG HT, RESTIFO NP: Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat. ImmunoL (2002) 3:999–1005.
  • DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298:850–854.
  • JIN P, WANG E: Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling. J. TransL Med. (2003) 1:8.
  • WANG E, MILLER LD, OHNMACHT GA et al.: Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. (2002) 62:3581–3586.
  • MARINCOLA FM: Translational medicine: a two way road. J TransL Med. (2003) 1:1.
  • PARMIANI G, COLOMBO MP: Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res. (1995) 5:295–301.
  • ANDERSEN MH, THOR STRATEN P: Survivin - a universal tumor antigen. HistoL HistopathoL (2002) 17:669–675.
  • BOON T, CEROTTINI JC, VAN DEN EYNDE B, VAN DER BRUGGEN P, VAN PEL A: Tumor antigens recognized by T lymphocytes. Annu. Rev. ImmunoL (1994) 12:337–365.
  • ROSENBERG SA: Cancer vaccines basedon the identification of genes encoding cancer regression antigens. ImmunoL Today (1997) 18:175–182.
  • OLD LJ, CHEN YT: New paths in human cancer serology. J. Exp. Med. (1998) 187:1163–1167.
  • LEE K-H, WANG E, NIELSEN MB et al.:Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. ImmunoL (1999) 163:6292–6300.
  • PITTET MJ, SPEISER DE, LIENARD D et al.: Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin. Cancer Res. (2001) 7:796s–803s.
  • THURNER B, HAENDLE I, RODER C et al.: Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. (1999) 190:1669–1678.
  • SCHEMENBOGEN C, SCHMITTEL A, KEILHOLZ U et al.: Phase II trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma./ Immunother. (2000) 23:275–281.
  • ZIMMERMAN PA, STEINER LL, TITANJI VP et al.: Three new DPB1 alleles identified in a Bantu-speaking population from central Cameroon. Tissue Antigens (1996) 47:293–299.
  • PARDOLL D: Editorial. Curr. Opin. ImmunoL (1994) 6:705–706.
  • KAECH SM, HEMBY S, KERSH E, AHMED R: Molecular and functional profiling of memory CD8 T cell differentiation. Cell (2002) 111:837–851.
  • WHERRY EJ, TEICHGRABER V, BECKER TC et al.: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. ImmunoL (2003) 4:225–234.
  • NATALI PG, NICOTRA MR, BIGOTTI A et al.: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. USA (1989) 86:6719–6723.
  • JAGER E, RINGHOFFER M, ALTMANNSBERGER M et aL: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer (1997) 71:142–147.
  • SELIGER B, MAEURER MJ, FERRONE S: TAP off- tumors on. ImmunoL Today (1997) 18:292–299.
  • SELIGER B, MAEURER MJ, FERRONE S: Antigen-processing machinery breakdown and tumor growth. ImmunoL Today (2000) 21:455–464.
  • OHNMACHT GA, WANG E, MOCELLIN S et al.: Short term kinetics of tumor antigen expression in response to vaccination. J. ImmunoL (2001) 167:1809–1820.
  • KAMMULA US, LEE K-H, RIKER A et al.: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. ImmunoL (1999) 163:6867–6879.
  • PANELLI MC, RIKER A, KAMMULA U et al.: Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases. J. ImmunoL (2000) 164:495–504.
  • PEREZ-DIEZ A, SPIESS PJ, RESTIFO NP, MATZINGER P, MARINCOLA FM: Intensity of the vaccine-elicited immune response determines tumor clearance. J ImmunoL (2002) 168:338–347.
  • MONSURRO V, NIELSEN MB, PEREZ-DIEZ A et al.: Kinetics of TCR use in response to repeated epitope-specific immunization. J. ImmunoL (2001) 166:5817–5825.
  • ZEA AH, CURTI BD, LONGO DL et aL:Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. (1995) 1:1327–1335.
  • LEE PP, YEE C, SAVAGE PA et cll.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. (1999) 5:677–685.
  • SPEISER DE, COLONNA M, AYYOUB M et al.: The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. J. Immunol. (2001) 167:6165–6170.
  • NIELSEN MB, MONSURRO V, MIGUELES S et al.: Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol. (2000) 165:2287–2296.
  • PITTET MJ, ZIPPELIUS A, SPEISER DEet al.: Ex vivo IFNI/ secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J. Immunol. (2001) 166:7634–7640.
  • APPAY V, NIXON DF, DONAHOE SM et al.: HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp. Med. (2000) 192:63–75.
  • HAMANN D, BAARS PA, REP MH et cll.:Phenotype and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. (1997) 186:1407–1418.
  • SALLUSTO F, LENIG D, FORSTER R, LIPP M, LANZAVECCHIA A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 401:659–660.
  • CHAMPAGNE P, OGG GS, KING A et al.: Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 410:106–111.
  • MONSURRO V, NAGORSEN D, WANG E et al.: Functional heterogeneity of vaccine-induced CD8+ T cells.j Immunol. (2002) 168:5933–5942.
  • MIGUELES SA, LABORICO AC, SHUPERT WL et al.: HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. (2002) 3:1061–1068.
  • VAN BAARLE D, KOSTENSE S, VAN OERS MH, MIEDEMA F: Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol. (2002) 23:586–591.
  • APPAY V, DUNBAR PR, CALLAN M et al.: Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. (2002) 8:379–385.
  • SPEISER DE, LIENARD D, PITTET MJ et al.: In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur. Immunol. (2002) 32:731–741.
  • MARINCOLA FM: IL-2 biological therapy. Cancer Updates (1994) 4(3):1–16.
  • ROSENBERG SA, LOTZE MT, YANG JC et al.: Experience with the use of high-dose IL-2 in the treatment of 652 cancer patients. Ann. Surg (1989) 210:474-84; discussion: 484–485.
  • BOON T, COULIE PG, VAN DEN EYNDE B: Tumor antigens recognized by T cells. Immunol. Today (1997) 18:267–268.
  • CORMIER JN, SALGALLER ML, PREVETTE T et al.: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/ Melan A [see comments]. Cancerj Sci. Am. (1997) 3:37–44.
  • ROSENBERG SA, YANG JC, SCHWARTZENTRUBER D et al.: Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. (1998) 4:321–327.
  • PANELLI MC, WANG E, PHAN G et al.:Genetic profiling of peripheral mononuclear cells and melanoma metastases in response to systemic IL-2 administration. Genome Biol. (2002) 3:RESEARCH0035.
  • WOLFEL T, KLEHMANN E, MULLER C, SCHUTT KH, MEYER ZUM BUSCHENFELDE KH, KNUTH A: Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp. Med. (1989) 170:797–810.
  • POCKAJ BA, SHERRY RM, WEI JP et al.:Localization of mindium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophospharnide and correlation with response. Cancer (1994) 73:1731–1737.
  • PANELLI MC, MARTIN B, NAGORSEN D et al.: A genomic and proteomic-based hypothesis on the eclectic effects of systemic IL-2 administration in the context of melanoma-specific immunization. J Invest. Dermatol. (2004) (In Press).
  • WANG E, MARINCOLA FM: A natural history of melanoma: serial gene expression analysis. Immunol. Today (2000) 21:619–623.
  • WANG E, MARINCOLA FM, STRONCEK D: Human leukocyte antigen (HLA) and human neutrophil antigen (HNA) systems. In: Hematology: Basic Principles and Practice. Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (Eds), Elsevier Science, Philadelphia, PA, USA (2003).
  • RUBIN JT, ADAMS SD, SIMONIST, LOTZE MT: HLA polymorphism and response to IL-2 bases therapy in patients with melanoma. Proc. Soc. Biol. Then Ann. Meet. (1991) 1:18.
  • MARINCOLA FM, SHAMAMIAN P, RIVOLTINI L et al.: HLA associations in the anti-tumor response against malignant melanoma. J Immunother. (1996) 18:242–252.
  • LEE JE, REVEILLE JD, ROSS MI, PLATSOUCAS CD: HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int. J Cancer (1994) 59(4):510–513.
  • HOWELL WM, BATEMAN AC, TURNER SJ, COLLINS A, THEAKER JM: Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. (2002) 3:229–232.
  • MCCARRON SL, EDWARDS S, EVANS PR et al.: Influence of cytokine gene polymorphism on the development of prostate cancer. Cancer Res. (2002) 62:3369–3372.
  • HOWELL WM, CALDER PC, GRIMBLE RF: Gene polymorphisms, inflammatory diseases and cancer. Proc. Nutr. Soc. (2002) 61:447–456.
  • WANG E, ADAMS S, ZHAO Y et al.: A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides. j Transl. Med. (2003) 1:4.
  • BITTNER M, MELTZER P, CHEN Y et al.: Molecular classification of cutaneous malignant melanoma by gene expression: shifting from a continuous spectrum to distinct biologic entities. Nature (2000) 406:536–840.
  • LENGAUER C, KINZLER KW, VOGELSTEIN B: Genetic instabilities in human cancers. Nature (1998) 396:643–649.
  • MOCELLIN S, PANELLI MC, WANG E, NAGORSEN D, MARINCOLA FM: The dual role of IL-10. Trends Immunol (2002) 24:36–43.
  • TANIGUCHI T: Transcription factors IRF-1 and IRF-2: linking the immune responses and tumor suppression. J. Cell. Physiol (1997)173:128–130.
  • DANIEL D, MEYER-MORSE N, BERGSLAND EK, DEHNE K, COUSSENS LM, HANAHAN D: Immune enhancement of skin carcinogenesis by CD4+ T cells. J. Exp. Med. (2003) 197:1017–1028.
  • HANAHAN D, LANZAVECCHIA A, MIHICH E: Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors. Cancer Res. (2003) 63:3005–3008.
  • WANG E, PANELLI MC, MARINCOLA FM: Genomic analysis of cancer. Princ. Pract Oncol (2003) 17:1–16.

Website

  • http://www.ncimelanomastudy.org/ National Cancer Institute clinical trials.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.